| Cat. No. |
Product Name |
CAS No. |
Information |
| H9598 |
Sovilnesib
|
2410796-79-9 |
AMG-650 is an oral, first in class, selective small molecule inhibitor of KIF18A for treatment of advanced solid tumors. |
| H8676 |
MPT0B390
|
1338320-90-3 |
MPT0B390 is a novel arylsulfonamide inducer, inhibits tumor growth, metastasis and angiogenesis with GI50 of 0.03 ± 0.01 μM±SD. |
| H2377 |
SR31527
|
311814-78-5 |
SR31527 is a novel allosteric Kinesin-like protein KIFC1 inhibitor that inhibits microtubule-stimulated KIFC1 ATPase activity with IC50 of 6.6 uM, binds directly to KIFC1 with Kd of 25.4 nM; prevents bipolar clustering of extra centrosomes in TNBC cells and significantly reducesTNBC cell colony formation and viability (MDA-MB-231, BT549 and MDA-MB-435s cells IC50=20-30 uM), with less toxicity to normal fibroblasts. |
| H2376 |
SB-743921
|
940929-33-9 |
SB-743921 is a potent, selective kinesin spindle protein (KSP) inhibitor with Ki of 0.1 nM, shows no activity against MKLP1, Kin2, Kif1A, Kif15, KHC, Kif4 and CENP-E; also shows high affinity for mouse KSP with Ki of 0.12 nM; blocks assembly of a functional mitotic spindle, thereby causing cell cycle arrest in mitosis and subsequent cell death in cancer cells, demonstrates improved potency over ispinesib in both biochemical and cellular assays; shows a broad spectrum of tumor inhibition in multiple cancer models. |
| H2375 |
S-Trityl-L-cysteine
|
2799-07-7 |
S-Trityl-L-cysteine (NSC 83265) is a potent, cell-permeable, selective inhibitor of mitotic kinesin Eg5, inhibits basal ATPase activity (IC50=1 mM) and microtubule-activated ATPase activity of Eg5 (IC50=140 nM); induces mitotic arrest in HeLa cells with an IC50 of 700 nM, and displays antitumor activity. |
| H2374 |
PVZB-1194
|
1141768-04-8 |
PVZB-1194 is a bis(hetero)aryl derivative that inhibits kinesin spindle protein (KSP) ATPase witn IC50 of 0.12 uM; inhibits HeLa cell proliferation with IC50 of 5.5 uM; potently inhibits KSP in a microruble dependent manner and induces a monoastral phenotype to arrest mitotic progression, abnormal KSP localization. |
| H2373 |
Propofol
|
2078-54-8 |
A widely used general anesthetic to induce and maintain anesthesia; influences ligand-gated channels, including the GABAA receptor and others; also inhibits conventional kinesin-1 KIF5B and kinesin-2 KIF3AB and KIF3AC, causing a significant reduction in the distances that these processive kinesins can travel without an effect on velocity (EC50
|
| H2372 |
PF-2771
|
2070009-55-9 |
PF-2771 is a potent, selective CENP-E inhibitor with IC50 of 16.1 nM; does not inhibit the ATPase activities of highly related kinesins (Eg5/KSP, chromokinesin and MCAK, IC50> 1 uM); selectively inhibits proliferation of basal breast cancer cell lines; regresses tumor growth correlated with increased phospho-HH3-Ser10 levels in a breast cancer xenograft tumor model. |
| H2371 |
Monastrol
|
329689-23-8 |
A potent, specific, allosteric and reversible mitotic kinesin Eg5 inhibitor with IC50 of 14 uM (microtubule motility inhibition); does not inhibit microtubule motility driven by conventional kinesin at 200 uM; inhibits both the basal and the microtubule-stimulated ATPase activity of the Eg5 motor domain, does not compete with ATP binding to Eg5; arrests cells in mitosis with monoastral spindles, and (S)-monastrol is a more potent inhibitor of Eg5 activity in vitro and in vivo. |
| H2370 |
MK-8267
|
1146209-50-8 |
MK-8267 (SCH 2047069) is a potent, orally bioavailable, brain penetrant kinesin spindle protein (KSP) inhibitor with EC50 of 3 nM; inhibits a broader panel of 57 different tumor cell lines with IC50
|
$ USD
Select Your Country or Region